AGÕæÈ˹ٷ½

RTW Investments, LP and Roderick Wong reported beneficial ownership of 5,873,308 shares of Akero Therapeutics, representing 7.3% of the outstanding common stock. The ownership is reported as shared voting and shared dispositive power, with no sole voting or dispositive power recorded.

The percentage is calculated using 79,717,570 shares outstanding as reported by the company. The filing is an amendment to a Schedule 13G and discloses that the RTW Funds hold the right to receive dividends or sale proceeds on the reported shares.

Jonathan Young, Chief Operating Officer of Akero Therapeutics (AKRO), filed a Form 4 reporting transactions dated 08/12/2025. The filing shows transactions effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025. The report records an acquisition of 12,500 common shares (and concomitant acquisition of 12,500 stock option rights with an exercise/conversion price of $21.10) and two sales totaling 12,500 shares sold at weighted-average prices of $47.721 and $48.324, respectively.

Following the reported activity the filing lists 197,484 shares beneficially owned directly and derivative holdings of 69,982 option-related instruments. The filing discloses three irrevocable trusts each holding 20,000 shares for the benefit of the reporting person’s children and states the reporting person disclaims beneficial ownership of those trust shares. The option referenced vests in 48 equal monthly installments commencing December 8, 2021.

Akero Therapeutics insider sale by CEO and director Andrew Cheng. The Form 4 reports that Mr. Cheng, who serves as President and CEO and is a company director, executed sales of common stock on 08/11/2025 pursuant to a Rule 10b5-1 trading plan dated August 16, 2024. The filing lists three dispositions of 10,795, 18,805 and 400 shares, each shown as sales, with weighted-average price ranges disclosed in the footnotes.

The footnotes state the shares were sold in multiple transactions at prices ranging $47.40�$48.39, $48.41�$49.39, and $49.43�$49.44, respectively. The report also shows the amount of common stock beneficially owned following the reported transactions as 509,962, 491,157 and 490,757 shares on the corresponding lines. The Form 4 is signed by an attorney-in-fact and identifies the trades as executed under the 10b5-1 plan; no other financial or operational data is included.

Jane Henderson, a director of Akero Therapeutics (AKRO), reported insider transactions dated 08/12/2025 showing linked non-derivative and derivative activity. The filing shows an acquisition of 3,000 common shares associated with a stock option having a conversion/exercise price of $7.009, and a sale of 3,000 common shares at $47.457. Following the reported transactions the filing shows she beneficially owned 9,398 shares of common stock directly. The disclosure also states that the related options are vested and currently exercisable.

Akero Therapeutics (AKRO) submitted a Form 144 reporting the proposed sale of 50,000 shares of common stock via J.P. Morgan Securities LLC on NASDAQ, with an aggregate market value reported as $2,414,000 and approximately 79,988,975 shares outstanding. The filing shows the shares were acquired by a stock option exercise and the acquisition date, payment date and approximate sale date are all listed as 08/12/2025, with payment in cash.

The form discloses no securities sold in the past three months and includes the seller’s representation about not possessing undisclosed material adverse information. Several issuer/filer identification fields in the provided content are blank, so the filing text here omits the named filer and named person for whose account the securities are to be sold.